What Is Arimidex

Last updated: June 11, 2026

TL;DR

Arimidex (anastrozole) is the aromatase inhibitor most commonly used by men running testosterone or other aromatizing steroids to control estrogen. Standard dose is 0.25-0.5 mg every other day on a 500 mg/week test cycle. It blocks the conversion of testosterone to estradiol by inhibiting the aromatase enzyme, preventing gyno, water retention, and emotional sides. Crashing estrogen below 20 pg/mL is worse than running high – dose carefully and bloodwork-guided.

What is Arimidex?

Arimidex (anastrozole) is a third-generation aromatase inhibitor (AI) originally developed by AstraZeneca for estrogen-receptor-positive breast cancer treatment in post-menopausal women. It binds to the aromatase enzyme reversibly, blocking the conversion of androgens (testosterone, androstenedione) into estrogens (estradiol, estrone). In the steroid world, it became the go-to AI for managing on-cycle estrogen because it works at low doses, has a long half-life, and lacks the cortisol-elevating side effects of exemestane.

What does Arimidex actually do?

Three documented effects on cycle:

• Lowers serum estradiol by 50-80% at therapeutic doses
• Prevents aromatization-driven gyno before it starts
• Reduces water retention that comes from elevated estrogen

Bonus effect: by reducing estrogen feedback at the hypothalamus, it can also bump testosterone production slightly in men still producing endogenously – useful for TRT users running low-dose protocols.

What dose should you run?

Dose-by-cycle reference for healthy male users:

• TRT (100-150 mg test/week): 0.25 mg twice per week, or as needed
• Beginner cycle (300-500 mg test/week): 0.25-0.5 mg every other day
• Intermediate cycle (500-750 mg test/week): 0.5 mg EOD
• Advanced cycle (1000+ mg test/week): 0.5-1 mg EOD

Stop dose adjustment at the level where estradiol sits 20-40 pg/mL on a sensitive assay. Going lower causes joint pain, low libido, depression, and lipid crash. We covered the dosing math for typical TRT in our Arimidex dose for 250 mg test guide.

When during a cycle should you start it?

Two protocols based on user goals:

• Preventive: Start at 0.25 mg EOD from week 1, adjust based on week-4 bloodwork. Avoids the bloat-and-crash cycle of waiting for symptoms.
• Reactive: Start only when estrogen symptoms appear (sensitive nipples, water retention, mood swings). Lower total Arimidex exposure but risk of symptomatic delay.

The preventive approach wins for first-time users. The reactive approach works for users who already know their personal aromatase response from prior cycles.

What bloodwork should you track?

Key panel for Arimidex management:

• Estradiol (sensitive assay only – not the standard LC-MS or immunoassay for males)
• Total testosterone, free testosterone, SHBG
• Lipid panel – Arimidex worsens lipids when estrogen drops too low
• CBC – hemoglobin and hematocrit (test-driven, not Arimidex-driven)

Estradiol on the sensitive assay is the only marker that actually drives Arimidex dose decisions. The standard female-protocol assay is useless for male estrogen tracking. We cover the full bloodwork approach in our PCT and bloodwork guide.

What are the side effects?

Dose-dependent. At standard cycle doses:

• Joint pain or stiffness (most common)
• Lipid panel shift – LDL up, HDL down
• Reduced libido and erection quality if estrogen crashes
• Bone density loss on long-term use
• Mood changes (irritability or low mood)

Crashed estrogen feels worse than high estrogen. Many users push Arimidex too hard chasing zero bloat and end up with severe joint pain, soft erections, and depression. Dose conservatively.

Arimidex versus Aromasin (Exemestane)?

Both AIs, different mechanism. Arimidex is competitive and reversible – it binds the enzyme temporarily. Aromasin is suicidal and irreversible – it destroys the enzyme molecule, requiring new enzyme synthesis for activity to resume. Practical differences:

• Arimidex: 0.25-1 mg EOD, lower IGF-1 reduction, milder on lipids
• Aromasin: 12.5-25 mg EOD, no estrogen rebound after stopping, slight anabolic effect

Most users start with Arimidex for cost and dose flexibility, then switch to Aromasin if Arimidex causes lipid issues or rebound estrogen after discontinuing.

Should you use Arimidex during PCT?

Generally no. PCT aims to restart endogenous testosterone, which requires healthy hypothalamic signalling – and that signalling depends partly on estrogen feedback. Suppressing estrogen during PCT delays the natural restart. Use SERMs (Clomid, Nolvadex, Enclomiphene) instead – they block estrogen at the receptor level in target tissues while leaving the pituitary-hypothalamus loop active. Arimidex during PCT only makes sense if estrogen rebounds after stopping a heavy AI dose mid-cycle.

How fast does it work?

Arimidex has a 50-hour half-life and reaches steady state in 7-10 days. Acute estradiol drop is visible within 24-48 hours of the first dose. Symptomatic relief (bloat, mood, gyno itching) usually catches up to bloodwork by day 3-5. Mistime the dose schedule and you can swing between high and crashed estrogen – EOD dosing keeps the levels stable.

How can you tell if your Arimidex is real?

Real anastrozole comes as 1 mg uncoated white tablets or 0.5 mg tablets from underground labs. Pharmaceutical-grade (Astrazeneca Arimidex) has consistent imprint markings and a smooth white finish. Counterfeit Arimidex is one of the most common fake compounds because it is inexpensive to source, easy to press, and hard for the buyer to verify visually. The most reliable check is bloodwork – estradiol drop within 5-7 days of starting confirms active product. We cover the visual inspection process for similar compounds in our fake HGH guide – the same logic applies to AIs.

Is Arimidex legal in Canada?

Anastrozole is a Schedule F prescription drug in Canada – legal medical use only via prescription. Personal use possession is rarely prosecuted but importation for non-medical purposes is technically illegal. Federal classification is at the Health Canada Drugs and Health Products page.

Sources

• Mauras N, et al. Pharmacokinetics and dose-finding of aromatase inhibitor anastrozole in healthy young men. J Clin Endocrinol Metab, 2004.
• Llewellyn W. Anabolics. Body of Science Publishing, 11th ed.
• Health Canada Anastrozole product monograph, 2024 edition.